At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 73 enrolled
Drug / intervention
LY2334737drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating LY2334737 for Malignant Solid Tumor and 2 related conditions. Completed, enrolled 73 participants across 4 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Solid Tumor, Solid Tumor, Metastatic Tumor
CountriesFrance, Germany, United States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedJul 2012
Primary CompletionNov 2012
TodayJul 2026
First PostedJul 24, 2012
Enrollment StartSep 1, 2008
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.9 years ago
Interventions
LY2334737drug
Administered orally